TSR-042

dostarlimab · GlaxoSmithKline

Drug timelines are a Plus or Pro feature.

3 regulatory and trial events tracked for TSR-042, covering 2023-04-21 to 2026-04-02. Get the full timeline:

Most recent: Clinical Trial Update: TSR-022 (Anti-TIM-3 Antibody) and TSR-042 (Anti-PD-1 Antibody) in Patients With Liver Cancer [Phase 2]